Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
ConclusionsEfficacy equivalence was demonstrated between the two drugs, and safety profiles were similar. There were no meaningful differences in efficacy and safety between FKB238 or bevacizumab in patients with non-sq-NSCLC.Trial registration numberNCT02810457.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer